Rivus Pharmaceuticals Reports Success in Reducing Liver Fat with Phase 2 HU6 Trial for MASH Patients Rivus Pharmaceuticals' Phase 2 M-ACCEL trial of HU6 shows significant liver fat reduction in MASH patients, highlighting a promising treatment option.

Rivus Pharmaceuticals Reports Success in Reducing Liver Fat with Phase 2 HU6 Trial for MASH Patients #Clinical_Trial #MASH #Charlottesville #Rivus_HU6